A New Biotin Derivative?DOTA Conjugate as a Candidate for Pretargeted Diagnosis and Therapy of Tumors

Autor: Sabatino G. 1, Chinol M. 2, Paganelli G. 2, Papi S. 2, Chelli M. 3, Leone G. 1, Papini A. M. 1, De Luca A. 2, Ginanneschi M. 1&3

Publikováno v: Journal of medicinal chemistry 46 (2003): 3170–3173.
info:cnr-pdr/source/autori:Sabatino G. 1, Chinol M. 2, Paganelli G. 2, Papi S. 2, Chelli M. 3, Leone G. 1, Papini A. M. 1, De Luca A. 2, Ginanneschi M. 1&3/titolo:A New Biotin Derivative?DOTA Conjugate as a Candidate for Pretargeted Diagnosis and Therapy of Tumors/doi:/rivista:Journal of medicinal chemistry/anno:2003/pagina_da:3170/pagina_a:3173/intervallo_pagine:3170–3173/volume:46

The synthesis of a new biotin derivative, the (CO) reduced N-aminohexyl biotinamido derivative, designed to be serum biotinidase resistant, and its conjugation to the chelator DOTA through an amide bond at one of the four carboxymethyl chains are des

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::9b675aa439ebf24cf6278344f01f1def
https://publications.cnr.it/doc/16579